12/2
04:26 pm
ptct
Principal Spectrum Preferred Secs Active ETF declares monthly distribution of $0.0827 [Seeking Alpha]
Medium
Report
Principal Spectrum Preferred Secs Active ETF declares monthly distribution of $0.0827 [Seeking Alpha]
12/2
04:26 pm
ptct
Principal Investment Grade Corporate Active ETF declares monthly distribution of $0.0792 [Seeking Alpha]
Medium
Report
Principal Investment Grade Corporate Active ETF declares monthly distribution of $0.0792 [Seeking Alpha]
12/1
06:19 pm
ptct
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
12/1
04:30 pm
ptct
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/1
06:04 am
ptct
PTC Therapeutics (NASDAQ:PTCT) was downgraded by analysts at Royal Bank Of Canada from an "outperform" rating to a "sector perform" rating.
Medium
Report
PTC Therapeutics (NASDAQ:PTCT) was downgraded by analysts at Royal Bank Of Canada from an "outperform" rating to a "sector perform" rating.
11/29
07:23 pm
ptct
How The Sephience Launch Is Reshaping The Story For PTC Therapeutics's Valuation [Yahoo! Finance]
Medium
Report
How The Sephience Launch Is Reshaping The Story For PTC Therapeutics's Valuation [Yahoo! Finance]
11/29
11:56 am
ptct
A PTC Therapeutics (PTCT) Insider Sold 10,000 Shares for $795,000 [Yahoo! Finance]
Medium
Report
A PTC Therapeutics (PTCT) Insider Sold 10,000 Shares for $795,000 [Yahoo! Finance]
11/26
02:14 pm
ptct
PTC Therapeutics (NASDAQ:PTCT) had its "hold (c)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
PTC Therapeutics (NASDAQ:PTCT) had its "hold (c)" rating reaffirmed by analysts at
Weiss Ratings.
11/25
05:01 am
ptct
Sandisk to join S&P 500; UPWK, FIBK, HBI to be part of S&P SmallCap 600 [Seeking Alpha]
Low
Report
Sandisk to join S&P 500; UPWK, FIBK, HBI to be part of S&P SmallCap 600 [Seeking Alpha]
11/20
01:38 pm
ptct
PTC Therapeutics (NASDAQ:PTCT) had its "hold (c)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
PTC Therapeutics (NASDAQ:PTCT) had its "hold (c)" rating reaffirmed by analysts at
Weiss Ratings.
11/20
08:22 am
ptct
PTC Therapeutics to Host R&D Day [Yahoo! Finance]
Low
Report
PTC Therapeutics to Host R&D Day [Yahoo! Finance]
11/20
08:00 am
ptct
PTC Therapeutics to Host R&D Day
Low
Report
PTC Therapeutics to Host R&D Day
11/11
06:22 pm
ptct
PTC Therapeutics, Inc. (PTCT) Presents at UBS Global Healthcare Conference 2025 Transcript [Seeking Alpha]
Low
Report
PTC Therapeutics, Inc. (PTCT) Presents at UBS Global Healthcare Conference 2025 Transcript [Seeking Alpha]
11/6
06:17 am
ptct
PTC Therapeutics: Sephience Starts Well, But Translarna Is The Swing Factor [Seeking Alpha]
Low
Report
PTC Therapeutics: Sephience Starts Well, But Translarna Is The Swing Factor [Seeking Alpha]
11/5
02:21 pm
ptct
PTC Therapeutics (NASDAQ:PTCT) had its price target raised by analysts at TD Cowen from $50.00 to $63.00. They now have a "hold" rating on the stock.
Low
Report
PTC Therapeutics (NASDAQ:PTCT) had its price target raised by analysts at TD Cowen from $50.00 to $63.00. They now have a "hold" rating on the stock.
11/5
12:25 pm
ptct
PTC Therapeutics (NASDAQ:PTCT) had its price target raised by analysts at Royal Bank Of Canada from $70.00 to $82.00. They now have an "outperform" rating on the stock.
Low
Report
PTC Therapeutics (NASDAQ:PTCT) had its price target raised by analysts at Royal Bank Of Canada from $70.00 to $82.00. They now have an "outperform" rating on the stock.
11/5
11:03 am
ptct
PTC Therapeutics (NASDAQ:PTCT) had its "sell" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Low
Report
PTC Therapeutics (NASDAQ:PTCT) had its "sell" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
11/5
11:02 am
ptct
PTC Therapeutics (NASDAQ:PTCT) had its "hold" rating reaffirmed by analysts at Cowen Inc.
Low
Report
PTC Therapeutics (NASDAQ:PTCT) had its "hold" rating reaffirmed by analysts at Cowen Inc.
11/5
08:04 am
ptct
PTC Therapeutics (NASDAQ:PTCT) was given a new $68.00 price target on by analysts at Barclays PLC.
Low
Report
PTC Therapeutics (NASDAQ:PTCT) was given a new $68.00 price target on by analysts at Barclays PLC.
11/5
07:19 am
ptct
PTC Therapeutics (NASDAQ:PTCT) had its "neutral" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
PTC Therapeutics (NASDAQ:PTCT) had its "neutral" rating reaffirmed by analysts at Citigroup Inc..
11/5
07:01 am
ptct
PTC Therapeutics (NASDAQ:PTCT) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Low
Report
PTC Therapeutics (NASDAQ:PTCT) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
11/5
04:22 am
ptct
PTC Therapeutics narrows 2025 revenue guidance to $750M–$800M as Sephience launch accelerates [Seeking Alpha]
Low
Report
PTC Therapeutics narrows 2025 revenue guidance to $750M–$800M as Sephience launch accelerates [Seeking Alpha]
11/4
04:25 pm
ptct
PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
Low
Report
PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
11/4
04:01 pm
ptct
PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Medium
Report
PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
11/1
07:21 pm
ptct
What Catalysts Could Shift the Narrative for uniQure After Breakthrough AMT-130 Data? [Yahoo! Finance]
Low
Report
What Catalysts Could Shift the Narrative for uniQure After Breakthrough AMT-130 Data? [Yahoo! Finance]